InVivo Therapeutics Holdings Corp. (NVIV): Price and Financial Metrics


InVivo Therapeutics Holdings Corp. (NVIV): $4.86

0.03 (+0.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NVIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

NVIV Stock Price Chart Interactive Chart >

Price chart for NVIV

NVIV Price/Volume Stats

Current price $4.86 52-week high $23.19
Prev. close $4.83 52-week low $3.50
Day low $4.80 Volume 7,100
Day high $4.90 Avg. volume 21,463
50-day MA $6.32 Dividend yield N/A
200-day MA $11.45 Market Cap 6.76M

InVivo Therapeutics Holdings Corp. (NVIV) Company Bio


InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 and is based in Cambridge, Massachusetts.


NVIV Latest News Stream


Event/Time News Detail
Loading, please wait...

NVIV Latest Social Stream


Loading social stream, please wait...

View Full NVIV Social Stream

Latest NVIV News From Around the Web

Below are the latest news stories about Invivo Therapeutics Holdings Corp that investors may wish to consider to help them evaluate NVIV as an investment opportunity.

InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Drops -488.24% From Highs, What Happens Next?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV)s traded shares stood at 0.71 million during the last session, with the companys beta value hitting 1.01. At the close of trading, the stocks price was $0.34, to imply a decrease of -7.43% or -$0.02 in intraday trading. The NVIV shares 52-week high remains $2.00, putting it -488.24% down since InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) Drops -488.24% From Highs, What Happens Next? Read More »

Marketing Sentinel | February 12, 2022

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., January 06, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming virtual H.C. Wainwright BioConnect Conference, which runs from January 10 – 13, 2022. Dr. Toselli’s presentation will provide an overview of the company and will also highlight

Yahoo | January 6, 2022

Is Now A Good Time To Invest In InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV)?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 10.97% to the previous days close as strong demand from buyers drove the stock to $0.56. Actively observing the price movement in the last trading, the stock closed the session at $0.50, falling within a range of Is Now A Good Time To Invest In InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV)? Read More »

Stocks Register | November 26, 2021

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference

CAMBRIDGE, Mass., September 09, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Annual Global Investment Conference, which runs from September 13 – 15, 2021. The conference will be held in a virtual format.

Yahoo | September 9, 2021

InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study

CAMBRIDGE, Mass., September 08, 2021--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has enrolled 15 patients with acute spinal cord injury into the INSPIRE 2.0 Study, or 75% of the total 20-patient enrollment target for the study. The INSPIRE 2.0 study is a randomized, controlled trial (20-patient, 10 subjects in each study arm), that is designe

Yahoo | September 8, 2021

Read More 'NVIV' Stories Here

NVIV Price Returns

1-mo -8.82%
3-mo -31.98%
6-mo -64.40%
1-year -71.09%
3-year -99.38%
5-year -99.99%
YTD -57.38%
2021 -43.69%
2020 -87.99%
2019 -85.11%
2018 -92.16%
2017 -81.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5832 seconds.